In vitro studies on susceptibility of Acanthamoeba castellanii to selected chemical agents

Acta Parasitologica

Volumn 50, Issue 1, 2005, Pages 25-31

  Chomicz, Lidia ^a   Zebrowska, Justyna ^a   Piekarczyk, Janusz ^a   Starościak, Bohdan ^a   Myjak, Przemysław ^b   Walski, Michał ^c   Kazimierczuk, Zygmunt ^c,d  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

^c MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^d WARSAW UNIVERSITY OF LIFE SCIENCES   (Poland)

Author keywords

Acanthamoeba castellanii; Protozoa; Susceptibility to chemicals; Ultrastructure

Indexed keywords

ACANTHAMOEBA CASTELLANII; BACTERIA (MICROORGANISMS); PROTOZOA;

EID: 17144377516     PISSN: 12302821     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Aksozek A., McClellan K., Howard K., Niederkorn J.Y., Alizadeh H. 2002. Resistance of Acanthamoeba castellanii cysts to physical, chemical and radiological conditions. Journal of Parasitology, 88, 621-623.
2. Ares-Mazas E., Gomez-Couso H., Paniagua-Crespo E. 2004. Feeding process of Acanthamoeba on Cryptosporidium oocysts. IX European Multicolloquium of Parasitology, 18-23 July 2004, Valencia, Spain. Book of Abstracts, 224.
3. Bartolome R., Villa M., Ortega A., Morales J.L., Calatayud M. 2004. The increasing clinical importance of free-living acanthamoebid species. IX European Multicolloquium of Parasitology, 18-23 July 2004, Valencia, Spain. Book of Abstracts, 222.
4. Casper T., Basset D., Leclercq C., Fabre J., Peyron-Raison N., Reynes J. 1999. Disseminated Acanthamoeba infection in a patient with AIDS: response to 5-fluorocytosine therapy. Clinical Infectious Diseases, 29, 944-945.
5. Červa L., Novak K. 1968. Amoebic meningoencephalitis, sixteen fatalities. Science, 160, 92.
6. Chomicz L., Piekarczyk J., Starościak B., Fiedor P., Piekarczyk B., Wojtowicz A., Szubińska D., Świderski Z., Rebandel H. 2001. Host-protozoans-bacteria-fungi interrelations in the mouths of patients with systemic illnesses. Wiadomoṡci Parazytologiczne, 47, 559-563.
7. Chomicz L., Piekarczyk J., Starościak B., Fiedor P., Piekarczyk B., Szubińska D., Zawadzki P.J., Walski M. 2002. Comparative studies on the occurrence of protozoans, bacteria and fungi in the oral cavity of patients with systemic disorders. Acta Parasitologica, 47, 147-153.
8. Chomicz L., Piekarczyk J., Zawadzki P.J., Piekarczyk B., Świderski Z., Bednarczyk A. 2000. Occurrence of oral protozoans in relation to oral cavity status in patients of different population groups. European Journal of Cell Biology, 52, Suppl., 79, 130.
9. Essig A., Heinemann M., Simnacher U., Marre R. 1997. Infection of Acanthamoeba castellanii by Chlamydia pneumoniae. Applied and Environmental Microbiology, 63, 1396-1399.
10. Ferrante A. 1991. Free-living amoebae: pathogenicity and immunity. Parasite Immunology, 13, 31-47.
11. Garcia L.S. 2001. Diagnostic medical parasitology. ASM PRESS, Washington.
12. Gatti S., Cevini C., Bruno A., Penso G., Rama P., Scaglia M. 1998. In vitro effectiveness of povidone-iodine on Acanthamoeba isolates from human cornea. Antimicrobial Agents and Chemotherapy, 42, 2232-2234.
13. Hughes R., Dart J., Kilvington S. 2003. Activity of the amidoamine myristamidopropyl dimethylamine against keratitis pathogens. Journal of Antimicrobial Chemotherapy, 51, 1415-1418.
14. Khan N.A. 2003. Pathogenesis of Acanthamoeba infections. Microbial Pathogenesis, 34, 277-285.
15. Kilic A., Tanyuksel M., Sissons J., Jayasekera S., Khan N.A. 2004. Isolation of Acanthamoeba isolates belonging to T2, T3, T4 and T7 genotypes from environmental samples in Ankara, Turkey. Acta Parasitologica, 49, 246-252.
16. Kilvington S., Hughes R., Byas J., Dart J. 2002. Activities of therapeutic agents and myristamidopropyl dimethylamine against Acanthamoeba. Antimicrobial Agents & Chemotherapy, 46, 2007-2009.
17. Kilvington S., Larkin D.F., White D.G., Beeching J.R. 1990. Laboratory investigation of Acanthamoeba keratitis. Journal of Clinical Microbiology, 28, 2711-2725.
18. Kopańska K., Najda A., Żebrowska J., Chomicz L., Piekarczyk J., Myjak P., Bretner M. 2004. Synthesis and activity of 1H-benzimidazole and 1H-benzotriazole derivatives as inhibitors of Acanthamoeba castellanii. Bioorganic & Medicinal Chemistry, 12, 2617-2624.
19. Larkin D.F.P., Kilvington S., Easty L. 1990. Contamination of contact lens storage cases by Acanthamoeba and bacteria. British Journal of Ophthalmology, 74, 133-135.
20. Lloyd D., Turner N.A., Khunkitti W., Hann A.C., Furr J.R., Russel A.D. 2001. Encystation in Acanthamoeba castellanii. development of biocide resistance. Journal of Eukaryotic Microbiology, 48, 11-16.
21. Martinez A.J. 1980. Is Acanthamoeba encephalitis an opportunistic infection? Neurobiology, 30, 567-574.
22. Martinez A.J., Visvesvara G.S. 1997. Free-living, amphizoic and opportunistic amebas. Brain Pathology, 7, 583-598.
23. Mazur T., Hadaś E., Iwanicka I. 1995. The duration of the cyst stage and the viability and virulence of Acanthamoeba isolates. Tropical Medicine and Parasitology, 46, 106-108.
24. Murdoch D., Gray T.B., Cursons R., Parr D. 1998. Acanthamoeba keratitis in New Zealand, including two cases with in vivo resistance to polyhexamethylene biguanide. Australian & New Zealand Journal of Ophthalmology, 26, 231-236.
25. Niszl I.A., Markus M.B. 2001. Treatment of acanthamoebic keratitis. XI International Congress of Protozoology ICOP, 15-19 July 2001, Salzburg, Austria. Book of Abstracts, 75.
26. Pérez-Santonja J.J., Kilvington S., Hughes R., Tufail A., Matheson M., Dart K.G. 2003. Persistently culture positive Acanthamoeba keratitis. In vivo resistance and in vitro sensitivity. Ophthalmology, 110, 1593-1600.
27. Rodriguez-Zaragoza S., Magana-Becerra A. 1997. Prevalence of pathogenic Acanthamoeba (Protozoa: Amoebidae) in the atmosphere of the city of San Luis Potosi, Mexico. Toxicology & Industrial Health, 13, 519-526.
28. Schuster F.L. 1993. Comparative effects of selected azole compounds on trophic and cystic stages of Acanthamoeba polyphaga. Journal of Eukaryotic Microbiology, 40, 563-569.
29. Schuster F.L. 2002. Cultivation of pathogenic and opportunistic free-living amebas. Clinical Microbiology Reviews, 15, 342-354.
30. Schuster F.L., Buck S., Rosenthal R.A., Schlech B.A. 2003. Efficacy of myristamidopropyl dimethylamine (Aldox®) against corneal isolates of Acanthamoeba spp. Journal of Eukaryotic Microbiology, 50, Suppl., 520-521.
31. Schuster F.L., Jacob L.S. 1992. Effects of magainins on ameba and cyst stages of Acanthamoeba polyphaga. Antimicrobial Agents & Chemotherapy, 36, 1263-1271.
32. Schuster F.L., Visvesvara G.S. 2004a. Free-living amoebae as opportunistic and non-opportunistic pathogens of humans and animals. International Journal for Parasitology, 34, 1001-1027.
33. Schuster F.L., Visvesvara G.S. 2004b. Opportunistic amoebae: challenges in prophylaxis and treatment. Drug Resistance Updates, 7, 41-51.
34. Schwarzwald H., Shah P., Hicks J., Levy M., Wagner M.L., Kline M.W. 2003. Disseminated Acanthamoeba infection in a human immunodeficiency virus-infected infant. Pediatric Infectious Disease Journal, 22, 197-199.
35. Seal D. 2003a. Acanthamoeba keratitis update-incidence, molecular epidemiology and new drugs for treatment. Eye, 17, 893-905.
36. Seal D. 2003b. Treatment of Acanthamoeba keratitis. Expert Review of Anti-infective Therapy, 1, 205-208.
37. Teknos T.N., Poulin M.D., Laruentano A.M., Li K.K. 2000. Acanthamoeba rhinosinusitis: characterization, diagnosis and treatment. American Journal of Rhinology, 14, 387-391.
38. Turner N.A., Russell A.D., Furr J.R., Lloyd D. 2000. Emergence of resistance to biocides during differentiation of Acanthamoeba castellanii. Journal of Antimicrobial Chemotherapy, 46, 27-34.
39. Van Hamme C., Dumont M., Delos M., Lachapelle J.M. 2001. Cutaneous acanthamoebiasis in a lung transplant patient. Annales de Dermatologie et de Venereologie, 128, 1237-1240.
40. Visvesvara G.S. 1993. Epidemiology of infections with free-living amebas and labolatory diagnosis of microsporidiosis. Mount Sinai Journal of Medicine, 60, 283-288.
41. Walochnik J., Aspöck H. 2001. Classification of the free-living amoebae: state of knowledge. XI International Congress of Protozoology ICOP, 15-19 July 2001, Salzburg, Austria. Book of Abstracts, 3.
42. Walochnik J., Duchene M., Seifert K., Obwaller A., Hottkowitz T., Wiedermann G., Eibl H., Aspöck H. 2002. Cytotoxic activities of alkylphosphocholines against clinical isolates of Acanthamoeba spp. Antimicrobial Agents & Chemotherapy, 46, 695-701.
43. Walochnik J., Haller-Schober E.-M., Kölli H., Picher O., Obwaller A., Aspöck H. 2000a. Discrimination between clinically relevant and nonrelevant Acanthamoeba strains isolated from contact lens-wearing keratitis patients in Austria. Journal of Clinical Microbiology, 38, 3932-3936.
44. Walochnik J., Obwaller A., Aspöck H. 2000b. Correlations between morphological, molecular biological, and physiological characteristics in clinical and nonclinical isolates of Acanthamoeba spp. Applied and Environmental Microbiology, 4408-4413.
45. Walochnik J., Picher O., Aspöck C., Ullmann M., Sommer R., Aspöck H. 1999. Interactions of "Limax amoebae" and gram-negative bacteria: Experimental studies and review of current problems. Tokai Journal of Experimental and Clinical Medicine, 23, 273-278.
46. Walochnik J., Sommer K., Obwaller A., Haller-Schober E.M., Aspöck H. 2004. Characterisation and differentiation of pathogenic and non-pathogenic Acanthamoeba strains by their protein and antigen profiles. Parasitology Research, 92, 289-298.
47. Winiecka-Krusnell J., Linder E. 2001. Bacterial infections of free-living amoebae (Review). Research in Microbiology, 152, 613-629.